The US Food and Drug Administration approved Jiangsu Hengrui Medicine's (SHA:600276) abbreviated new drug application for its paclitaxel albumin-bound injection, according to a Friday filing with the Shanghai Stock Exchange.
The injection is indicated for the treatment of breast and pancreatic cancer, among other cancers, the filing said.
Shares closed 5% lower during Friday's trading.
Price (RMB): ¥50.20, Change: ¥-2.4, Percent Change: -4.51%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments